Viral infections of the respiratory tract caused by respiratory syncytial virus (RSV) and adenovirus contribute significantly to the morbidity and mortality after allogeneic stem cell transplantation. Up to date there is no established antiviral treatment against these pathogens. Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against RSV and adenovirus in vitro. Since the clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects, the application of intravenous ribavirin may be a safer therapeutic alternative. In a retrospective analysis we identified 22 patients who received intravenous ribavirin after adenovirus or RSV detection in the respiratory tract. Fifteen of these patients showed symptoms of lower respiratory tract infection. Intravenous ribavirin was started after a median of 4 days after virus isolation and continued for a median of 9 days. It was combined with cidofovir in 7 patients. In 6 out of 8 patients treated because of RSV isolates from the respiratory tract the virus was no longer detectable after treatment. The remaining 2 patients died shortly after initiation of treatment and could not be analysed for virus persistence. The median survival for those patients who cleared the virus was 252 days (range 88 -1133+ d). Four of these patients died 3 to 12 months after RSV detection from causes unrelated to the virus. In case of adenovirus isolates the treatment was efficacious in eradicating the virus from the respiratory tract in more than 60%. The median survival for patients who cleared the virus was 302 days (range 74 -630+d) as compared to 178 days (range 39 -394+d) in patients with persisting virus despite antiviral therapy. 60% of the patients with clearance of adenovirus are still alive and surviving for at least 8 months after virus detection. Using Kaplan Meier estimates there was a strong trend (p=.081, log Rank test) towards a better survival in patients responding to treatment with documented clearance of adenovirus. In conclusion, these data provide some evidence that intravenous ribavirin is efficacious in eradicating RSV and adenovirus isolates from the respiratory tract in recipients of allogeneic stem cell transplants, but these data have to be confirmed by controlled clinical trials.
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Clinical implications of HHV-6 infection in pediatric hematology and oncology patients H. J. Dornbusch, V. Strenger, W. Schwinger, H. Lackner, P. Sovinz, S.W. Aberle, C. Urban (Graz, Vienna, A) Objectives: Reactivation of HHV-6 in immunocompromised patients, particularly following stem cell transplantation, was first reported in 1991. Meanwhile numerous clinical manifestations have been linked to HHV-6 infection such as pneumonitis, sinusitis, gastroenteritis, hepatitis, encephalitis, myelosuppression, complete bone marrow failure and exacerbation of GvHD. The aim of this study was to add to the current knowledge of the pattern of HHV-6 related symptoms in this patient population. Methods: 69 immunocompromised patients after conventional or high dose chemotherapy were routinely tested for presence of HHV-6 DNA in blood according to a w eekly viral screening schedule. In addition, blood or other samples were examined on suspicion of viral infection resulting in a total of 597 samples tested. Results: HHV-6 DNA could be amplified in 96 samples derived from 15 patients. HHV-6 PCR positivity in blood was mainly associated with myelosuppression, enteritis, pneumonia and GvHD and coincided with amplification of CMV-DNA in 8/15 patients. In 3 patients with tissue proven HHV-6 enteritis as well as myelosuppression simultaneously examined blood samples were negative. Further details are outlined in the table.
Conclusion: HHV-6 should be considered as a potential cause of multiple clinical manifestations occurring in immunocompromised patients. Routine PCR screening particularly after stem cell transplantation opens the possibility of preemptive therapy. Even if samples of peripheral blood are tested negative, an aggressive search for viral DNA in affected tissue is justified on clinical suspicion in light of a life threatening, but potentially treatable infection.
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Infectious complications following allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning regimen D. Caldera, F. Montanari, L. Malcovati, P. Bernasconi, A.A. Colombo, C. Baraté, M. Lazzarino, E.P. Alessandrino (Pavia, I) Infectious complications contribute significantly to morbidity and mortality in patients undergoing an allogeneic transplant. Reduced-intensity preparative regimens have been developed to reduce TRM and to extend the procedure to aged pts or with comorbidities. This approach should shorten post-transplant cytopenia but it is unclear whether or not it is able to reduce the infectious risk. We studied the post-transplant incidence of infections in 19 pts with a median age of 50 years (24-55), affected with AML (9 pts), MDS (6), NHL (2), HD (1), ALL (1), submitted to allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning regimen. All pts were at high risk of infection due to previous fungal pneumonitis (2 pts), HBV or HCV hepatitis (2), rectal fistula (1) or co-morbidities proning to infections (mitral stenosis, diabetes, interstitial lung fibrosis) or active hematologic disease (6 MDS, 3 lymphoma, 3 AML pts). The preparative regimen consisted of Thiothepa 10 mg/kg and Fludarabine 125 mg/m2. GvHD prophylaxis was performed with Cyclosporin A (CsA) 1.5 mg/kg/day c.i. and MTX 10 mg/m2 on day +1, and 8 mg/m2 on day +3, +6, +11. After engraftment, CsA was given 3 mg/kg bd per os up to day +100, and than in absence of GvHD, tapered 20% every two weeks. The median time to neutrophil recovery was 15 days (range 10-18). Fourteen pts had a febrile episode responsive to antibiotics during the neutropenic phase, while 8 pts had asymptomatic bacterial (3) or fungal (5) positive culture from skin or mucosa.
CMV infection was detected earlier (6 to 11 days) in 4 out 7 episodes by AVL and CA-PCR assays than by Ag. Moreover, in 1 episode AVL detected infection 7 days earlier than CA and Ag. The AVL-PCR assay was capable of monitoring both increases and decreases in the CMV viral load with same efficacy as the CA-PCR and the pp65 antigenemia assay. Conclusions: The affigene® CMV VL assay (AVL-PCR) showed a good correlation with the CA and the Ag assays. The AVL assay is also capable of monitoring increases and decreases in the CMV viral load. This quantitative CMV PCR seems a useful tool in CMV monitoring after SCT.
P449
Royal College of Paediatrics and child health: best practice statement on immunization in the immunocompromised child R. Skinner, E.G. Davies, A.J. Cant, A. Finn, A. Foot 
on behalf of the Working Party on Immunisation in Immunocompromised Children, Royal College of Paediatricians and Child Health, London, UK
Background: Haemopoietic stem cell transplantation (HSCT) is a common secondary cause of major immunodeficiency. Although opportunistic organisms are considered to pose the most serious infective threat to immunocompromised children, common bacterial and viral infections against which immunisations are available may also cause substantial late morbidity or even death. Many studies have documented low specific antibody concentrations after HSCT, and restoration of protective titres in most children after reimmunisation, but there is little published data about immunisation in other groups of immunocompromised children. Nevertheless, most such children are likely to benefit from continuation or commencement of active immunisation, provided certain live vaccines are avoided when appropriate. Unfortunately, proof of benefit in terms of reduced morbidity and mortality
is not yet available in any group of immunocompromised children. Despite broad recommendations concerning immunisations in these children, clinical practice has varied, particularly concerning the content and timing of immunisation schedules. Methods: A Working Party of the Royal College of Paediatrics and Child Health (RCPCH) was convened to develop guidelines for immunisation of immunocompromised children, including HSCT recipients. Results: Information was collated from formal computerised searches of the literature, expert committee reports, and advice from respected authorities. The lack of controlled trials prevented development of evidence-based guidelines. Instead a "Best Practice Statement" (BPS) was written. The BPS includes detailed recommendations for re-immunisation after HSCT, as well as immunisation in the following groups of children: 1) primary immunodeficiency, 2) after standard chemotherapy, 3) after solid organ transplantation, 4) inflammatory diseases / other immunosuppressive treatment, 5) HIV infection, 6) other groups. The recommendations are available on the RCPCH website (http://www.rcpch.ac.uk/publications/recent_publications/Immuno comp.pdf). Conclusions: The introduction of the BPS should allow a consistent approach to immunisation of immunocompromised children, including reimmunisation post-HSCT. It is anticipated that this will facilitate audit and stimulate further research necessary to generate the solid evidence base that is required to support future recommendations in recipients of HSCT and other groups of immunocompromised children.
P450
Single center experience of adenovirus infection post BMT for primary immunodeficiency M. A. Slatter, P. Atkinson, R. Warren, A. Bhattacharya, C. Taylor, T.J. Flood, W. Abinun, R. Skinner, A.J. Cant, A.R. Gennery (Newcastle upon Tyne, UK) Introduction: Adenoviral disease is a significant cause of mortality after BMT, particularly mismatched or unrelated donor transplants. No studies have looked at adenoviral infection during BMT specifically in PID patients. Methods: We performed a retrospective analysis of patients undergoing BMT for PID at our centre in whom adenovirus infection was detected. Patients were identified from laboratory data (positive adenovirus culture and/or PCR result). Only those with a positive result in the peri-transplant period were included in the study.
Results: We have transplanted 130 patients for PID since 1987. 19 patients (15%) with positive adenoviral cultures received 22 transplants for SCID (3 patients) or combined immunodeficiency (16 patients). 21 received cytoreductive conditioning. 11 received whole marrow. There were 2 matched sibling, 14 MUD, 5 haploidentical and 1 cord blood donor. 14 BMT's were associated with adenovirus gastroenteritis alone, 8 with disseminated disease. A variety of treatments were used in 14, including immunoglobulin, ribavarin, ganciclovir & cidofovir. 7 children died, 4 deaths (3%) were attributable to disseminated adenoviral disease despite aggressive antiviral treatment. Adenovirus type 40/41, an enteric strain, was detected in 4 of 8 patients with disseminated disease, 3 of whom died. Grade 3 GvHD necessitated intensive immunosuppression in 1 patient who subsequently died from disseminated adenoviral disease. Poor outcome was not consistently associated with donor type or matching, marrow T cell depletion, or timing of detection of adenovirus. More intense immunosuppression was associated with fatal outcome. 3 of 4 who died from adenoviral disease had a CD3 count <200 cells/microlitre at time of death. The 2 surviving patients who had disseminated disease were transplanted within the last year. Early detection of adenovirus in the blood by PCR enabled prompt aggressive treatment with cidofovir and may have contributed to survival. Conclusion: Adenoviral disease is a significant cause of mortality post BMT for PID, which is more commonly associated with intensive immunosuppression and prolonged T cell depletion. Surprisingly, enteric adenovirus type 40/41may disseminate, and caused 1 of our attributable deaths. New detection methods such as PCR enable earlier detection, and early, more aggressive treatment which may improve outcome.
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B-cell expansion post transplant is more frequent in patients receiving fludarabine and anti-T-lymphocyte globulin as a part of conditioning regimen and was associated with IFN gamma IntronI polymorphic features A. Lange, A. Klimczak, B. Wysoczanska, D. Dlubek, A. Mlynarczewska, J. Dybko (Wroclaw, PL) Oligo-or monoclonal B cell expansion may reflect EBV reactivation in pts. on immunosuppression post HSCT. 58 patients (pts.) post HSCT (30 matched sibling and 28 alternative donors transplantations) received standard BuCy (15), BuCy+ATG (12) and non-myeloablative ATG+Flu (31) conditioning. In all pts. peripheral blood lymphocytes profile and lymph nodes status was followed. In 14 pts. a proportion and/or the count of CD20+ cells exceeded the mean value + 1SD of the whole group in a given time intervals post transplant. In addition in 3 out of these 14 pts. enlargement of lymph nodes was noticed. These fourteen pts. were diagnosed as having B cell expansion. 34 and 24 pts. were below and after 180 days post transplant, respectively. Pts. with early B cells expansion had frequently arthralgia and fever in variance in those with a high level of blood CD20+ cells later than 180 days post transplantation jaundice and blood transaminase level elevation were seen. Pts. with the increase of blood level of CD20+ cells received more frequently Flu and ATG in conditioning regimen as compared to those lacking blood CD20+ cells expansion (0.79 vs 0.45, p=0.03). A similar association was not seen when ATG was considered separately. Enlarged lymph nodes showed diffuse infiltration of CD20+ cells and in two cases with a substantial contribution of CD38+, CD138+ cells. The cells were BCL2 and p53 negative. Either CD138+ or CD20+ cells were IRF4 positive and a small proportion of cells were LMP1 positive. This staining profile was suggestive of EBV reactivation. We have no a direct proves whether EBV was also responsible for an increase of CD20+ cells in pts. lacking lymphadenopathy. However the clinical picture was very suggestive and in 6 pts. an increase in the number of EBV copies was found. All pts. were typed for the IFNgamma IntronI (CA)n microsatellite polymorphism by STR-PCR method. All pts. except one with B cell expansion lacked 2/2 genotype, known to be associated with a high IFNgamma production potential, as compared to other alleles (1/14 vs 13/41, p=0.06). In conclusion in pts. post transplant a syndrome characterized with elevation of CD20+ cells accompanied by fever, arthralgia and liver injury. This was seen in a substantial proportion of pts. and was associated with the employment of Flu and ATG immunosuppression as a part of the conditioning regimen and likely reflected reactivation of EBV or other yet not identified viruses.
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Epstein-Barr virus primary infection or reactivation is a frequent event after non-myeloablative allogeneic stem cell transplantation for hematological diseases and is associated with shorter overall survival B. Gueglio, P. Moreau, N. Morineau, B. Mahe, M. Vigier, V. Dubruille, J.L. Harousseau, N. Milpied (Nantes, F) Very little is known about the incidence and consequence of Epstein-Barr-Virus (EBV) infections following miniallografts. We investigated 31 successive patients (21 male and 10 female) with various haematological diseases (MM n=9; AML n=7; ALL n=2; MDS n=2; CML n=2; CLL n=3; NHL n=5; Hodgkin disease n=1) who received non myeloablative allogeneic peripheral blood stem cell transplantation from HLA identical sibling (n=30) or HLA-matched but unrelated (n=1) donor, from 08/1998 to 12/2001. Median time between diagnosis and miniallograft was 16 months (range 4-96), median age was 56 years (range 26-64), 17 patients were in complete remission and 15 had advanced disease. Patients had received a median of 2 lines of treatment (range 0 -6) and 21 had previously been grafted (autologous BMT n=16; conventional allogeneic BMT n=5). Recipient/Donor serologic viral status for EBV was: R-/D-n=1; R-/D+ n=5; R+/D-n=1 and R+/D+ n=24. Conditioning regimen associated fludarabine+busulfan and ATG, fludarabine +melphalan or Flagida in 27, 1 and 3 patients, respectively. GVHD prophylaxis consisted of ciclosporin alone (n=29) or +methotrexate (n=2). All patients but 3 engrafted. The most recent update was undertaken in 05/2002. Median OS was 12,5 months (range 1-46). Molecular quantification of EBV viral load was monitored by a quantitative real-time plasma polymerase chain reaction (PCR). Positive PCR was defined by more than 50 EBV genome equivalents/mL. EBV primary infection (n=2) or reactivation (n=10) occurred in 12 patients (39%), with a median time of detection for first EBV positive PCR of 26 days (range 12-67). Nine patients (29%) presented at least 2 successive EBV positive PCR: 2/9 showed decreasing of EBV viral load, 1/9 received Rituximab because of simultaneous documented lymphoma at day 100, 6/9 received this pre-emptive treatment and did not develop EBV associated lymphoma. Occurrence of EBV positive PCR tend to be associated with the use of ATG for conditioning regimen (p=0,08) and development of acute GVHD (p=0,07) and is associated with significantly shorter overall survival (median 5 months vs 32 months, p=0,05). In conclusion, there is a high incidence of EBV infections after miniallografts which is associated with a shorter overall survival, maybe reflecting an higher immunodepressive status of these patients. Pre-emptive therapy with Rituximab appears to be effective for preventing EBV associated lymphoma in these patients.
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Ex vivo reactivation of BKV-specific cytotoxic T-cells for the treatment of BKV-associated disease P. Comoli, S. Basso, R. De Sanctis, A. Moretta, G. Botti, A. Nocera, R. De Palma, F. Perfumo, F. Locatelli, R. Maccario, A. Azzi, F. Ginevri (Pavia, Florence, Genoa, Naples, I) Polyomavirus BK (BKV)-associated hemorrhagic cystitis is an important cause of morbidity and occasional mortality in patients receiving HSCT. In recipients of renal allograft (RTx), persistent active replication of the virus has been recently identified as an important cause of progressive graft dysfunction and graft loss. Currently, no established anti-viral treatment is available. In recipients of HSCT, anecdotal cases cured with antiviral drugs have been reported, while in RTx recipients control of viral replication is tentatively obtained by means of reduction of immunosuppression, with consequent increased risk of graft rejection. Thus, there is a need to develop alternative therapeutic tools able to control the infection. Adoptive cellular immunotherapy has proven to be a successful approach for prevention and/or treatment of Epstein-Barr virus-and cytomegalovirus-related complications in the immunocompromised host. To assess the feasibility of translating this strategy to the prevention of BKV-associated disease, we optimized a procedure for the ex-vivo reactivation of BKV-specific cytotoxic T cells (CTLs) from peripheral blood lymphocytes (PBL) of BKV-seropositive healthy donors and renal transplant patients. In detail, dendritic cells were pulsed with inactivated BKV and employed as antigen-presenting cells, in the presence of cytokines. The CTL lines, in addition to CD3+/CD8+ and CD3+/CD4+ lymphocytes, included also variable numbers of gammadelta/CD3+ and CD3+/CD56+ cells endowed with BKVdirected, MHC-class I-unrestricted cytotoxic activity (MHC-UCA). The BKV specificity of the lines was indicated by an efficient lysis of BKV-infected targets, with little or no reactivity observed against non-infected autologous or HLA-mismatched targets. In vitro killing of allogeneic BKV-infected targets, likely due to CTLs displaying MHC-UCA, was also displayed. This latter phenomenon could be of crucial importance for the success of a CTL-based treatment of BKV nephropathy, as the epithelial cells bearing the latent virus are of donor origin, and would therefore not be a suitable target for patient's HLA-restricted C TLs. Overall, our preliminary data hold promise for defining a CTLbased immunotherapy approach to BKV-related complications in transplant recipients.
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Control of viral shedding of rotavirus into the stool by intravenous ribavirin in patients with severe GVHD of the gut following allogeneic hematopoietic stem cell transplantation M. Schleuning, H. Buxbaum-Conradi, G. Jäger, H.-J. Kolb (Munich, Kassel, D) Severe GVHD of the gut is a serious and often fatal complication after allogeneic stem cell transplantation. Due to the destroyed mucosal barrier concomitant viral infections occur quite often and possibly worsen the disease in part by again triggering GVH reactions. Therefore in these cases it seems rationale to combine the immunosuppressive GVHD treatment with specific antiviral drugs. Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses. In a retrospective analysis we identified seventeen patients who received intravenous ribavirin throughout the years 1998 and 2001 after rotavirus detection in the stool during the course of severe diarrhea due to GVHD of the gut. Three patients received more than one cycle of intravenous ribavirin because of persistent or relapsing viral contamination. Therefore a total of 20 treatment cycles are analysed. Rotavirus was the sole viral pathogen only in 2 of the 20 treatment cycles, usually there was coinfection with adenovirus. Intravenous ribavirin was combined with cidofovir on 11 occasions. Rotavirus shedding was controlled after Ribavirin treatment in 70% of cases as assessed after a median of 14 days. On three occasions there was documented persisting viral shedding and in two cases there was no control assessment. In half of the patients in whom viral shedding was controlled also the gastrointestinal symptoms improved and in further 5 patients the clinical condition at least remained stable. However, in 4 of the patients who initially cleared the virus, it was again detectable 2-4 weeks later. All patients with documented persisting virus died after a median of 167 days after virus detection, whereas 40% of the patients with documented and persisting control of viral shedding are long term survivors who are still alive after a median of 704 days after virus detection. In summary, intravenous ribavirin seems to be of some benefit in patients suffering from severe GVHD of the gut complicated by rotavirus infection. However, controlled clinical trials are needed to establish the role of the drug in managing this clinical situation.
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Qualitative plasma PCR assay versus pp65 antigenemia assay for monitoring CMV infection and preemptive ganciclovir/foscavir therapy in allogeneic hematopoietic stem cell transplantation: single center experience B. Zawilinska, D. Hawrylecka, P. Mensah, A.B. Skotnicki (Krakow, PL) Introduction: Cytomegalovirus (CMV) infection remains a significant cause of morbidity and mortality in SCT. A variety of CMV diagnostic tests have been used for the surveillance of CMV infection but a limited number of studies have directly compared the diagnostic utilities of qualitative plasma CMV DNA PCR assay and antigenemia (AG) and theier suitability for guiding preemptive therapy in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Patients and m ethod: 25 consecutive patients undergoing allogeneic HSCT in our Department between 1999-2002 were included. All pts received HSC from related donors: (AML-9, ALL-3, CML I CP-10, CLL-1, SAA-1). The CMV serostatus of the transplant recipients and donors were as follows: donor and recipient positive 17/25, donor negative and recipient positive 3/25, donor positive and recipient negative 3/25 (CMV high risk group), donor and recipient negative 2/25 (CMV low risk group). Patients were given standard antimicrobial prophylaxis consisted of ciprofloxacin at 500mg bid, fluconazole 400mg p.o. daily, and acyclovir 800mg p.o. bid. Patients were monitored by both methods -twice a week (for high risk) and weekly (for low risk) until day +100, and thereafter every other week until day +180. Preemptive gancyclovir or foscavir therapy (induction for 14 days or until the patient was negative by AG followed by 1 month of maintenance therapy) was initiated at the time of a single positive AG result, diagnosis by PCR required 2 consecutive positive results. Results: A total of 20 CMV infections were detected in 25 pts. Positivity of CMV DNA PCR was the only marker of CMV viremia in 6/20 episodes, both assays were positive for 12/20 CMV infections, 2/20 episodes of CMV viremia were diagnosed on the basis of single positive AG result. The sensivities of the CMV DNA PCR and pp65 antigenemia assay for the detection of CMV infection in our series were 90% and 70% respectivly. 2 CMV high risk pts. with positive results of both assays simultanesly progressed to CMV end-stage organ disease despite the preemptive therapy. Conversion of the AG result to a negative upon administration of ganciclovir or foscavir therapy occured a median of 8 days earlier than conversion of the plasma CMV DNA PCR. Conclusions: CMV DNA PCR assay is more sensitive than AG assay for guiding the initiation of the preemtive therapy and the latter appears to be more suitable for monitoring a patient's response to antiviral therapy.
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Early detection of Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplant and preemptive therapy with four courses of i.v. cydofovir A. Dominietto, E. Tedone, M. Soracco, S. Bregante, C. di Grazia, F. Gualandi, T. Lamparelli, A.M. Raiola, M.T. van Lint, F. Frassoni, A. Bacigalupo (Genoa, I) Background: Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplant (SCT) and a number of these patients progress to develop a lymphoproliferative disease (LPD). The latter can be predicted by early detection of increasing EBV load by quantitative polymerase chain reaction (Q-PCR) (van Esser et al, Blood 2001; 98,972) . Objectives: Aim of the study is to evaluate the effect of early treatment with cydofovir after EBV reactivation monitored by Q-PCR in 48 patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) from an HLA identical sibling (n=10) or an alternative donor (n=38). Methods: EBV monitoring was performed every week in alternative donor HSCT and at the onset of clinical symptoms in HLA-identical siblings and is expressed as DNA copies x 105 cells. Antiviral prophylaxis was given to all patients (high dose acyclovir or foscarnet. Patients with two consecutive assays (=>100 EBV DNA copies) were treated with cydofovir 5 mg/Kg i.v./weekly for 4 doses, along with reduction or temporary stop of immunosuppressive therapy. Median follow-up of patients is 168 days (range 15-699). Results: We could identify 4 groups of patients. (a) 21 patients (44%) remained EBV negative and their transplant related mortality (TRM) is 9%. (b) 9 patients had EBV reactivation (100-500 copies), were not treated (for various reasons) and their TRM is 33%. (c) 9 patients had EBV reactivation (100-1000 copies) were given cydofovir, and their TRM is 11%. (d) 9 patients had EBV reactivation (>1000 copies) and their TRM is 33%. Of the 18 patients treated with cydofovir: 12 patients (66%) had complete response to cydofovir; 3/18 patients with high EBV load were treated with rituximab and DLI for progression to EBV-LPD. Conclusions: EBV reactivation is a frequent event after allogeneic HSCT, as identified by Q-PCR, and can be treated successfully with cydofovir when EBV DNA copies are <1000. When the EBV DNA load exceeds 1000 copies, cydofovir does not prevent evolution towards EBV-LPD and therapy with rituximab should probably the first line treatment.
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Measles after allogeneic stem cell transplantation: a single center experience K. Matsumoto, K. Kato, Y. Hidaka, N. Yoshida, T. Matsuyama (Nagoya, JP) Background: Recently in Japan, the rate of vaccination of measles decreased to 70-80% and regional outbreaks of measles have been evolved. Measles induces a transient profound immunosuppression and severe lymphopenia, which may lead to fatal opportunistic infections. Patients: A total of 69 children undergoing allogeneic stem cell transplantation between Jan. 1998 and Dec. 2001 at Children's Medical Center, Japanese Red Cross Nagoya First Hospital were included (22 Related BMT, 40 URBMT, 7 CBSCT). In this cohort we experienced 4 cases (5.8%) of measles defined by serology or PCR during the outbreaks in [2001] [2002] . One more case of measles who was transplanted in 1993 and had been complicated with severe cGVHD was included in the analysis. Results: Underlying disease were ALL(3y, CBSCT and Liver transplantation), Hurler syndrome(4y, URBMT(twice)), sAML (18y, URBMT), SAA(23y, URBMT) and ALL(23y, Related BMT). Measles were acquired 24,19,34,28 and 114 months respectively after transplantations. Exanthema was observed atypically in 4 cases and Koplik spots could be observed only in one case. Laboratory tests revealed left shifts of WBC and elevation of Creactive protein and LDH. All three cases with pneumonia had been treated with steroid because of cGVHD or Evans syndrome. Three patients were successfully treated with gamma globulin and antibiotics. One patient with SAA died of pneumonia despite of the intensive treatment of ribavirin, gamma globulin and antibiotics. The other patient with pneumonia (Hurler syndrome) was treated by ribavirin, vitamin A, gamma globulin and antibiotics, but measles genome detected by PCR did not decrease. After several administrations of autologous activated CD4+ and whole T cells, viral load dramatically diminished two months after the onset of measles, and the severe pneumonia was resolved with DLI, autologous activated T cells infusion, sivelestat sodium hydrate and antibiotics three months later. Conclusions: Measles after stem cell transplantation is severe in immunocompromised recipients especially with steroid therapy. Nation wide strategy for prevention and therapeutic approach for measles should be reassessed.
P458 Association of BK virus with hemorrhagic cystitis and successful treatment with cidofovir

C.L. Wong, C. Williams, R. Chopra, K. Mutton (Manchester, UK)
Objectives: To determine the association between BK virus and haemorrhagic cystitis (HC) and to ascertain the effectiveness of Cidofovir in the treatment of BK-associated HC. Method: We conducted a prospective study of 44 pts undergoing chemotherapy, PBSCT and BMT. The association between HC and BK virus was studied by monitoring the urinary excretion of BK virus using electron microscopy and polymerase chain reaction. Urine dipstick analysis was performed daily on all pts. Result: HC occurred in 8 of 44 (18.1%) patients (7 had allogeneic PBSCT/BMT and 1 had chemotherapy). BK viruria (<= 1 positive sample) was detected in all the 8 (100%) patients with HC and in 6 (16.7%) of the remaining 36 patients without HC. BK viruria was detected in 14 of 44 (31.8%) patients undergoing various treatments. 8 of 14 (57%) developed HC whilst none of the 30 BK-negative patients developed this complication. The occurrence of HC and BK viruria was related to the source of the PBSC/BM (p<0.0123). HC occurred in 7 of 17 (41.2%) allogeneic PBSCT/BM recipients whilst none of the 8 autologous PBSCT recipients developed HC. Among the 17 recipients of allogeneic PBSCT/BMT, BK viruria was detected in 12 (70.6%) patients. 7 of the 12 (58.3%) patients developed HC. Occurrence of BK viruria (but not HC) was also shown to be related to the primary disease (p=0.0046). However, the incidence of HC and BK viruria were unrelated to treatment regimes and occurrence of graft-versus-host-disease. The association between HC and BK was shown to be statistically significant (p < 0.0001). Treatment of 4 out of the 8 patients with HC associated with BK viruria with Cidofovir resulted in resolution of HC and a reduction in the BK virus load. None of these patients demonstrated any side-effects to Cidofovir. Conclusion: We conclude that there is a significant association between BK virus and HC. In the event of failed conservative measures, Cidofovir may be used to treat BK-associated HC. However, patients should be monitored closely for side effects to this drug.
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Outcomes of cytomegalovirus antigenemia following peripheral blood stem cell transplantation in high-risk pediatric patients V. Hazar, S. Kansoy, A. Kupesiz, S. Aksoylar, M. Kantar, A. Yesilipek (Antalya, Izmir, TR) Cytomegalovirus (CMV) disease remains an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are many efforts directed towards prevention, early diagnosis and treatment of CMV disease following HSCT. Assay for CMV early antigen pp65 on circulating leukocytes is a sensitive and specific method for CMV reactivation and detects CMV replication in the bloodstream before the advent of disease. There is no consensus about the duration of intensive surveillance for CMV after transplantation. We examined the frequency, risk factors and outcomes of a positive CMV antigen assay in 65 high-risk pediatric patients done peripheral blood stem cell transplantation (PBSCT). All patients and donors had positive CMV serology before transplantation. The incidence of antigenemia in this cohort was 21.5%, a median of 22.5 days post-PBSCT. These frequencies were 28.3% and 5.3% in allogeneic and autologous groups, respectively (p=0.05). P atients with nonmalignant disease had higher CMV antigenemia than patients with malignant disease (33.3% vs 6.9%, p=0.01). Age at PBSCT, sex, graft versus host disease (GVHD) prophylaxis regimen and presence of acute GVHD did not affect the risk of CMV antigenemia. None of antigenemic patients developed CMV disease. These findings suggest that CMV reactivation incidence is similar to those in patients performed bone marrow transplantation. Intensive surveillance in the presence of positive pre-transplant CMV serology may be enough for post-transplant six months if peripheral blood is used for stem cell resource. Additionally, CMV reactivation did not seem to be a risk for CMV disease in pediatric patients done PBSCT.
P460 Cytomegalovirus infection following T-cell depleted allogeneic stem cell transplantation: comparison between two different methods of T-cell depleted
S. Chakrabarti, D. Milligan, J. Brown, D. Pamphilon, H. Osman, D. Marks (Birmingham, Bristol, UK)
We compared between two T cell depleted (TCD) regimens, the pattern and outcome of cytomegalovirus (CMV) infections treated pre-emptively with antiviral drugs, guided by PCR and antigenemia assays. One group (group A; n=29, UD= 13) received CD34+ selected grafts with T cell addback (median 5 x 104/kg) and the other (group B; n=32, unrelated donor [UD]=8) received grafts T cell depleted with Campath-1H 'in the bag', both following full intensity conditioning. Group A, in addition, received Campath-1H in-vivo from day -9 to -5. Twenty patients in group A and 14 patients in group B were at-risk of CMV disease and underwent monitoring with PCR-assay (group B) or both PCR and antigenemia assays (group A). The probability of reactivation was 74.6% in group A (13/20) at a median of 19 days (1-55) and 42.9% in group B (5/14) [p=0.08] at a median of 52 days (9-75). Recurrence of CMV infection occurred in 10/12 evaluable patients in group A (probability 83.4%) and 1/5 patients in group B (probabiliy 20%) (p=0.02). Late reactivation (>100 days) was noted in 9/18 evaluable patients in group A (probability 58.1%) and 1/13 in group B (probability 7.7%) [p=0.008]. The duration of positive PCR/antigenemia positivity (79 vs 16.6 days, p= 0.03) and antiviral therapy (86 vs 19.1 days, p=0.02) were significantly longer in group A, both at the first and subsequent reactivation. The mean absolute lymphocyte count(x 109/l) at 30 days (0.27 vs 0.42, p=0.03) and 100 days (0.76 vs 1.4, p= 0.01) were significantly lower in group A in CMV at-risk patients, but not in CMV low-risk group. However, only two patients developed CMV disease in each group with two deaths in group A and one in group B. The CMV reactivation, recurrence and ALC recovery were not influenced by UD graft, high-risk disease status or recipient age, but only by the method of TCD. The non-relapse mortality and overall survival were 40% and 55.7% in group A compared to 22% and 71% for group B in CMV at-risk patients and 25% and 55.6% in group A and 17% and 62.8% in group B in CMV low-risk patients (p=0.5). Thus patients conditioned with Campath in-vivo and receiving CD34+ selected graft with TCAB experienced significantly more CMV reactivation, recurrence and persistence with a longer duration of treatment. But with extended preemptive therapy, the incidence of CMV d isease and overall survival was similar to patients receiving grafts incubated with Campath-1H.
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Successful oral ribavirin therapy for severe hemorrhagic cystitis associated with allogeneic stem cell transplantation C.P. Vaz, A. Campos, A. Marinho, F. Campilho, I. Baldaque, S. Almeida, I. Oliveira, I. Pazos, A. Carvalhais, P. Pimentel (Porto, P) Hemorrhagic cystitis (HC) is a well-known complication after blood and marrow transplantation (BMT).Adenovirus (AdV) are increasingly recognized pathogens that affect BMT recipients. The clinical spectrum of AdV infection is from asymptomatic viruria to disseminated disease and the overall mortality rate is high. We report four cases of severe hemorrhagic cystitis associated with allogeneic BMT: All four had received sibling BMTs (Three HLA matched and one HLA mismatched). Conditioning regimen were: myeloablative (busufan + cyclophosfamide) =2 and nonmyeloablative (busulfan + fludarabine) =2. Graft-versus-host disease (GVHD) grade ¡Ý 2 was present in all patients at the onset of symptoms. The diagnosis was made in a presence of positive urine samples tested by indirect immunoflourescent test with a specific monoclonal antibody against AdV (Biotrim,Ireland) and typical clinical features (dysuria, suprapubic pain, gross hematuria, renal impairment with ultrasonic pyelocalicial ectasy) negative urine culture and negative tests from BK virus, CMV and JC virus. Oral ribavirin (10-15 mg/Kg tid) was started with improvement in clinical symptoms and negativity for virus tests that were well correlated after two to three weeks of continuous treatment. The HLA mismatched recipient had HC recurrence and recovered after a second treatment. All patients experienced mild pancytopenia during the ribavirin course that recovered after ceasing the treatment. In our experience oral ribavirin was been effective and well tolerated for severe hemorrhagic cystitis caused by adenovirus pathogens in allogeneic BMT. The immunoflourescent test has shown a good correlation with clinical course and seems to be a reliable method of diagnosis of adenovirus infection.
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Clinical significance of Epstein-Barr virus DNA load monitoring after hematopoietic stem cell transplantation B. Gruhn, A. Meerbach, R. Häfer, D. Fuchs, J. Hermann, P. Wutzler, F. Zintl (Jena, D) Epstein-Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a serious complication following hematopoietic stem cell transplantation (HSCT). In 70 patients undergoing HSCT in a single center we prospectively performed a quantitative EBVspecific polymerase chain reaction in peripheral blood mononuclear cells (PBMCs) weekly after HSCT. We observed an EBV reactivation (>10e3 EBV-genome copies/10e5 PBMCs) only in patients who received antithymocyte globulin (ATG) for immunosuppression. 12 of 38 patients (32%) who received ATG experienced EBV reactivation. Interestingly, we found a similar incidence of EBV reactivation in 5 of 15 patients (33%) who received ATG (Fresenius) and in 7 of 23 patients (30%) who received ATG (Sangstat). However, in patients with ATG (Fresenius) EBV reactivation was observed only in the range between 10e3 and 10e4 EBV-genome copies/10e5 PBMCs and no EBV-associated LPD occurred. In contrast, in patients with ATG (Sangstat) EBV reactivation was always greater than 10e4 EBV-genome copies/10e5 PBMCs and 4 patients developed EBV-associated LPD at a median of 80 days after HSCT. The increase of EBV-genome copies occurred 1-5 weeks before the S93 onset of LPD. After treatment of LPD 3 of 4 patients demonstrated a dramatic decrease of EBV-genome copies and survived, while the fourth patient died of lymphoma. All 4 patients with EBV-associated LPD presented with a high copy number (>10e4 EBV-genome copies/10e5 PBMCs). In contrast, 63 patients who had a copy number lower than 10e4 EBV-genome copies/10e5 PBMCs did not develop EBV-associated LPD (P < 0.001). This finding prompted us to start preemptive therapy in patients with a high copy number for prevention of EBVassociated LPD. Three patients developed a high viral load (>10e4 EBV-genome copies/10e5 PBMCs). Preemptive therapy was performed with a single dose of rituximab (375 mg/sqm) at a median of 52 days after HSCT. Following administration of rituximab a dramatic decrease of EBV-genome copies and B cells was observed. In all 3 patients no EBV-associated LPD occurred until 6 months after rituximab infusion. We conclude that EBV DNA load monitoring allows early diagnosis and treatment of EBV-associated LPD following HSCT. A high increase of EBV-genome copies significantly predicts for EBVassociated LPD. Preemptive therapy with rituximab leads to a dramatic decrease of EBV-genome copies and B cells and appears to be effective for preventing EBV-associated LPD.
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Cytomegalovirus infection surveillance with nested-PCR and antigenemia assays in patients receiving/not receiving ganciclovir universal prophylaxis in HLA identical sibling hematopoieic stem cell transplants S. H.A. Bonon, C.L. Rossi, C.A. De Souza, A.C. Vigorito, S.C.B. Costa (Campinas, BR) Cytomegalovirus (CMV) remains a cause of significant morbidity and mortality after allogeneic hematopoietic stem cell transplants (HSCT). Objetive: Antigenemia and N-PCR were compared for monitoring active HCMV infection after allogeneic stem cell transplants. Methods: We prospectively follow up 69 HLA identical sibling donor HSCT patients for evidence of active HCMV infection and disease starting in the day of transplant until day 150 after transplant. These patients were divided in two groups according the Institution Protocol: Group A: 45 recipients with malignance diseases and with risk factor for HCMV disease (D+/R+; D-/R+ and D+/R-) received ganciclovir universal prophylaxis in a dose of 5 mg/kg per day, 3 days per week and continued until day 75 after transplant; Group B: 16 patients with non-malignance diseases and 8 pediatric patients didn't receive ganciclovir universal prophylaxis. These 69 patients were followed up for incidence of active HCMV infection by AGM and N-PCR. Results: In Group A, the probability of positive antigenemia at day 150 was 53%, with a median of first detection at day 62 (range 17 to 131 days) compared with a positive N -PCR of 71.3% and with a median of first detection at day 54 (range 0 to 145 days) (Wilcoxon test Pvalue = NS); the sensitivity and specificity of the antigenemia assay was 58% and 64.3%, respectively, using N-PCR as the gold standard test. In Group B, the probability of positive antigenemia at day 150 was 66.7%, with a median of first detection at day 34 (range 5 to 103 days), compared with a positive N-PCR of 67.2% and with a median of first detection at day 24 (range 0 to 86 days) (P = 0.03); the sensitivity and specificity of the antigenemia assay was 81.2% and 62.5%, respectively, using N -PCR as the gold standard test. Gastritis HCMV-disease occurred in 2/45 patients (4.44%) of the Group A and was successfully treated with ganciclovir. In Group B, 4/24 patients (16.7%) had HCMVdisease: one corioretinitis; two gastritis and one interstitial pneumonia (IP). Two deaths occurred in Group B (8.5%), one with IP and other with gastritis. Conclusion: Ganciclovir universal prophylaxis or preemptive treatment based on detection of antigenemia (AGM) or a nested polymerase chain reaction (N-PCR) may prevent HCMV disease during the first 100 days after transplant. Moreover, the universal prophylaxis did not reduce the HCMV active infection, and seems delay the N-PCR and AGM positivity.
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Infliximab as an immunomodulator in cytomegalovirus infection in an allogenic bone marrow transplant patient: case report R. Ovilla-Martinez, F. Perez-Zincer, R.M. Jimenez-Alvarado, A. Martinez, M. Reyes (Mexico, MEX)
Introduction: There is evidence that one of the mechanisms of tissular damage caused by cytomegalovirus (CMV) is immunemediated. Therapies that could hold or modify the immune response can be of benefit in patients with severe CMV infection. Case: A 33-year-old male was diagnosed with chronic myelogenous leukemia (BCR-ABL b2a2+). Although treated with hydroxyurea and interferon he rapidly progressed to accelerated phase with refractory splenomegaly for which he underwent splenectomy. He underwent an allogenic bone marrow transplant from a 5/6 matched unrelated donor (DR missmatch). He received conditioning with TBI 12.0 Gy and cyclophophamide 120mg/Kg and prophylaxis with cyclosporine and methotrexate. The neutrophil count reached >0.5 x 109/L by day +10 and the platelet count >25 x 109/L by day +30. By day +11 he developed grade II skin and liver GVHD which was treated with methylprednisolone and mofetil mycofenolate and a single dose of infliximab 5mg/Kg with disappearance of the GVHD. By day +14 he presented veno-occlusive hepatic disease and acute pulmonary edema which responded to sodium restriction, spironolactone, dopamine, and LMWH. He was discharged by day +30 in good condition to be re-admitted for pneumonitis 4 days later. Broncheal lavage cultures showed S. viridans and biopsy showed CMV interstitial pneumonitis. The CMV DNA load went up to 769pg/dL by day +48. He was treated initially with vancomycin, ganciclovir, acyclovir and immunoglobulin. He presented severe neutropenia on day +41 for which he received G-CSF and GM-CSF. On day +48 (14 days after his readmission) he presented rapid deterioration with severe respiratory failure without response to Bipap and fulfilling the criteria for intubation and mechanical ventilatory support. X rays showed an image characteristic of interstitial pneumonia. Before intubation, and as a last resource, 2.5mg/Kg of infliximab was administered. Eight hours later, the patient showed a dramatic improvement of his general condition and respiratory function. He stayed on Bipap with progressively lower concentrations of O2. By day +5 of the administration of infliximab, Bipap was discontinued and the chest X rays showed disappearance of the interstitial pneumonia. The patient was discharged in good condition nine days later. We propose that infliximab has a beneficial immunomodulatory role in severely ill patients with CMV infection. The exact mechanism remains to be elucidated.
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Cytomegalovirus antigenemia and the outcome of patients treated with preemptive ganciclovir: retrospective analysis of 233 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation M. Yanada, K. Yamamoto, N. Emi, R. Suzuki, N. Hamajima, K. Kitaori, Y. Morishima, Y. Kodera, H. Sao, Y. Morishita (Nagoya, JP) Objectives: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Preemptive strategy with ganciclovir (GCV) has been widely adopted using antigenemia assay or PCR as monitoring method for CMV reactivation. In this multicenter retrospective study, we evaluated 233 consecutive patients at risk who received allogeneic HSCT to investigate the relationship among antigenemia, GCV use, and the outcome.
Methods: Adult patients who underwent allogeneic HSCT in the Nagoya BMT Group between July 1997 and December 2000 were eligible for inclusion. Among 264 patients whose antigenemia data were available, 9 patients were excluded for seronegativity of both donor and recipient, and 22 patients for early death. Remaining 233 patients were monitored for CMV antigenemia, and the factors affecting antigenemia and CMV disease were analyzed. No patients received T cell-depleted transplants. Antigenemia-guided preemptive strategy with GCV was applied to all patients. Results: 162 patients (69.5%) documented antigenemia at a median onset of 35 days (range: 15-130), and 18 patients (7.7%) developed CMV disease at a median onset of 52 days (range: 20-245). Univariate analyses showed that age (>40), sex (male) and acute GVHD (grade II-IV) were significant risk factors for antigenemia, and acute GVHD for CMV disease. In multivariate Cox models, only acute GVHD had significant influence on both risks [hazard ratio: 1.66 (95% CI, 1.20-2.30) and 2.87 (95% CI, 1.13-7.30), respectively]. GCV use, as well as acute GVHD and age significantly increased the risk for bacterial or fungal infection after engraftment [hazard ratio: 3.30 (95% CI, 1.15-9.52)]. Those who developed CMV antigenemia showed poor prognosis as compared with those who did not (log-rank, P=0.042). Conclusions: Antigenemia documentation was a poor prognostic factor for HSCT patients, and acute GVHD had strong influence on development of CMV infection/disease. GCV use was associated with an increased risk for secondary bacterial or fungal infection, which might reflect an immunocompromised state of the patients. Optimal preemptive strategy for CMV disease should be established.
P466 Cytomegalovirus specific immune reconstitution after standard versus reduced-intensity conditioning and allogeneic hematopoietic cell transplantation M. Bornhäuser, J. Babatz, F. Walz, D. Bandt, G. Ehninger, U. Oelschlägel (Dresden, D)
Prospective monitoring of Cytomegalovirus (CMV) specific immune reconstitution was performed in 24 patients receiving allogeneic hematopoietic cell transplantation from related (n=8) and unrelated (n=16) donors. CMV specific CD8+ cells were quantified by FACS analysis using PE-labeled HLA class Itetramer complexes for HLA-A*0201 (495-503) and HLA-B*0702 (417-426). Most analyses are available for 4 months (n=20) and 12 months (n=9) after transplantation. All patients were screened weekly for pp65 antigen and CMV DNA using qualitative PCR. Of 20 patients analysed at 4 months, 13 had received fludarabinebased reduced intensity conditioning (RIC) whereas 7 patients had been transplanted after standard intensity regimens (SIR). The mean percentage of CD8+/tetramer+ cells at 4 months was 1.3 ± 1.9% after RIC and 0.8 ± 1.6% after SIR, respectively (p=0.11). At 12 months after transplantation tetramer analyses have been performed in 9 patients (4 RIC, 5 SIR), so far. The mean percentage of CD8+/tetramer+ events at 12 months was 0.55 ± 0.83% compared to 1.15 ± 1.8% at 4 months (p=0.77) for the whole patient group. We detected very low or no CD8+/tetramer+ events in CMV seropositive recipients with seronegative donors (n=5) even in case of CMV antigenemia or positive PCR results. No CMV antigenemia occurred in seronegative recipients with seropositive donors and no tetramer+ cells could be measured (n=3). Higher levels of CD8+/tetramer+ cells (> 1.5%) in the first 4 months were recorded in seropositive recipients 2-3 weeks after diagnosis and treatment of CMV reactivation. They were associated with successful clearance of pp65 antigen or CMV DNA. In two patients late CMV reactivation (12 and 18 months after transplantation) was associated with the concurrent elevation of CD8+/tetramer+ events and a detectable anti-CMV-IgM titer. In conclusion we observed a trend towards faster regeneration of CMV-specific CD8+ immunity in patients after RIC associated with CMV reactivation. More patients will be analysed in this prospective study to confirm our observation.
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Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients D.G. Wolf, N.S. Lurain, T. Zuckerman, R. Hoffman, J. Satinger, A. Honigman, N. Saleh, E.S. Robert, J.M. Rowe, Z. Kra-Oz (Jerusalem, IL; Chicago, USA; Haifa, IL) Preemptive ganciclovir therapy has reduced the ocurrence of early cytomegalovirus (CMV) disease after hematopoietic stem cell transplantation (HSCT). However, late disease is increasingly reported. We describe two patients who developed late CMV central nervous system (CNS) disease after haploidentical HSCT. Direct genotypic analysis was employed to examine the presence of ganciclovir resistance. One patient had a mixed viral population in the CSF, with coexistent wild type and mutant UL97 sequences. The presence of 2 different strains was confirmed by subclone sequencing of the UL54 gene. One of the strains was different from the concurrent blood strain. The second patient had resistant variant in the lungs . These cases raise concern about the changing natural history of CMV disease in HSCT, with emergence of previously uncommon manifestations following prolonged prophylaxis. Under these circumstances the CNS may be a sanctuary site, where viral persistence and antiviral drug resistance could result from limited drug penetration 
Background:
Epstein-Barr associated lymphoproliferative disease (EBV-LPD) are an infrequent but severe complication occurring after allogeneic HSCT. Epstein-Barr Virus (EBV) reactivation can also be responsible for cytopenia or fever in HSCT patients. The monitoring of the EBV viral load by quantitative PCR may permit to recognize EBV reactivation earlier and thus to introduce adapted treatment. However, only limited information is available concerning the clinical relevance of this approach. Of note, the impact of anti-viral drugs on the EBV viral load is not well documented in vivo. Method: In 7 patients, we prospectively monitored the EBV viral load by quantitative real-time PCR (LightCyclerTM, Roche Diagnostics), weekly during at least 3 months following HSCT. All patients were grafted for an hematological malignancy, either after a standard conditioning regimen with a matched unrelated donor (n=5), or after a non-myeloablative regimen with a sibling donor (n=2). The number of viral genome copies was quantified on peripheral blood mononuclear cells (PBMC) and on plasma. All donors and recipients had a positive serology for EBV. Results: In PBMC, the EBV viral load was positive (>10 copies/µg d'ADN) at least once in all patients except one. Only 2 patients had a positive viral load on plasma (>250 copies/mL), occurring at the time of the maximal viral load in PBMC (>105 copies/µg DNA in both cases). In one of them, we introduced valaciclovir (3g/day) because of suspected EBV-related profound cytopenia. This treatment was followed by a rapid decrease and negativation of the viral load in the plasma and in PBMC. In 2 patients, EBV reactivation occurred at the same time as CMV and VZV reactivation. These 2 patients were treated with ganciclovir and aciclovir, respectively, with a beneficial effect on the EBV viral load. No patient developed EBV-LPD. Interpretation: In our study, the fact that PCR was found frequently positive on PBMC indicates that quantification of the viral load is essential for clinical interpretation. The PCR on plasma is probably a more specific marker for significant EBV reactivation, and might be more relevant for clinical interpretation. In 3 cases, we observed a decrease of the EBV viral load under different anti-viral drugs. If this pharmacological control of EBV reactivation is confirmed in the larger cohort of patients we are currently studying, anti-viral drugs might be tested as pre-emptive treatment of EBV reactivation after HSCT.
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Real-time PCR for detection of respiratory viral pathogens in pediatric BMT patients R.G.M. Bredius, K.E. Templeton, S.A. Scheltinga, A.C.M. Kroes, J.M. Vossen, E.C.J. Claas (Leiden, NL) Respiratory viruses have become a well-recognized problem in the hematopoietic transplant (HSCT) population. Current techniques, such as culture and immunofluorescence (IF) may not have sufficient sensitivity to always obtain a viral diagnosis. Therefore, real-time PCR techniques with higher sensitivity were developed to assess the frequency of these infections in pediatric HSCT patients. A prospective study was performed in 41 pediatric patients in Leiden from April 2000 to April 2002. All patients were nursed in protected sterile environment until discharge and were held in "quarantine" until lymphocyte recovery. Nasal washes were taken from each patient prior to transplantation and 2, 4, 8 and 16 weeks post transplantation. Culture, IF and real-time PCR were performed on each sample. Real-time PCRs using molecular beacons as probes were developed for influenza A (FA), B (FB), parainfluenza virus (PIV) type 1, 2, 3, respiratory syncytial virus (RSV) and adenovirus (ADV). Real-time PCRs with molecular beacons as probes were developed for these viruses, and the recently described human metapneumovirus (hMPV). Allogeneic HSCT was performed for various malignant and nonmalignant diseases. The incidence of respiratory viruses detected in these patients was 5/41 (12%), 6/41 (15%) and 10/41 (24%) by IF, culture and real-time PCR, respectively. Analyses of 25 samples taken from the 5 patients with both IF and culture positive results, showed a significant increase in sensitivity by real-time PCR: 19/25 samples were positive whereas only 8/25 were detected by the conventional assays. Clinically relevant respiratory infections were seen in 3 patients: one patient had PIV1 (with relatively mild URTI and cough from day -2 to week +2), one had PIV3 (with cough, URTI and lower RTI, reappearance of virus was observed in IF and culture, while PCR was continuously positive from week -2 to +2), and one patient had RSV (with URTI and cough, from week +7 to +9). Only the PIV3 infection needed treatment with antiviral drugs. No nosocomial infections were observed. Of the 5 patients found positive by PCR only, two were ADV, one hMPV, one PIV1 and one PIV3. All were detected in a single sample on admission. Detection of respiratory viral infections is an important aspect in the management of BMT patients. The application of real-time PCR as a more sensitive tool for respiratory viral diagnosis could improve management of this infection in immunocompromised patients.
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The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after allogeneic hematopoietic cell transplantation E. A. Soydan, R. Idilman, M. Arat, S. Karayalcin, C. Ustun, M. Ozcan, O. Arslan, M. Beksac, O. Ilhan, H. Akan (Ankara, TR) Allogeneic hematopoietic cell transplantation (alloHCT) recipients are in an immune-compromised status for long periods and therefore at risk for hepatitis B virus infection (HBV) and reactivation after transplantation. We aimed to evaluate, the effect of donor HBV status on recipient HBV serology after alloHCT.Between January 1994-January 2002, a total of 139 eligible alloHCT recipients (101 peripheral bloods, 38 bonemarrows) and their donors were reviewed. 129 recipients were conditioned with cyclophosphamide (Cy) based regimen, four were conditioned with Cy and anti-thymosit globuline, and the remaining six received a reduced-intensity regimen. All recipients received short-term methotrexate and CsA (±mycophenolat mofetil) as GVHD prophylaxis. Donors were divided into four distinct groups. Group 1 (n=25) consisted of individuals, who were vaccinated, group 2 (n=40) consisted of individuals, who were naturally immunized, group 3 (n=4) consisted of individuals, who were HBs-Ag positive and group 4 (n=70) consisted of individuals, who were HBV-naive and n ot vaccinated.After transplantation, no HBV-related mortality was observed into four distinct groups. Eighty-eight percent of the HBV-vaccinated recipients, who had vaccinated-donors, seroconverted to antiHBs positivity (14/16). Four recipients (4/19, 21%), who received stem cells from HBV-immune donors, seroconverted to anti-HBs antibody after transplantation. Fifty-seven percent of previously vaccinated-recipients (8/14) who had vaccinated donors (group 1) and twenty-nine percent of previously HBV-immune recipients (7/24), who received stem cells from HBV-naive group (group 4) lost detectable anti-HBs antibody following transplantation, whereas only one HBV-immune recipient, who received stem cells from HBV-immune donors (group 2) lost detectable antiHBs antibody (57% vs 29% vs 6%; p= 0.001, p=0.05). Four recipients who received stem cells from HBV-naive groups (group 4) acquired a de-novo HBV infection after transplantation while there was no de-novo HBV infection was observed in the group 1 and 2 (4/70 vs 0/65; p=0.05). None of the recipients who had HBs-Ag positive donors prior to transplantation had evidence for acquired HBV infection after transplantation. Based upon these results, the HBV immune status of the donors plays an important role either on sero-conversion or a sustained antibody response in recipients of alloHCT after transplantation.
Additional abstracts to this topic
Lamivudine (3tc) for the prevention of hepatitis B flare-up during non-myeloablative allogeneic hematopoietic transplantation: a case report A. Caremani, S. Guidi, L. Lombardini, P. Rossi Ferrini, A. Bosi (Florence, I) HBV reactivation may represent an harmful problem during administration of high-dose chemotherapy. Recently 3TC has shown its effectiveness in suppressing HBV replication. We report a successful NST using 3TC in a refractory lymphoma patient (pt) complicated by chronic hepatitis B. In November 1996 to a 53-year old female, HBV-carrier for 12 years, was diagnosed a diffuse large B-cell lymphoma stage IVA for BM involvement. From January 1997 to January 2001 she was submitted to different protocols with important side effects. She presented two acute hepatitis which spontaneously recovered. In February 2001 she underwent a NST; 3TC (150mg/die) was used to prevent hepatitis flare-up. Pt's status at NST was PR. The preparative regimen consisted of fludarabine, melphalan and sdTBI; GVHD prophylaxis was CSA and MMF. On day 0 were infused 3,8 x 106 CD34 cells/Kg b.w. Days with ANC<500 n 5; PLT aphereses n 1; no infectious episodes occurred. Discharged on day +14, was maintained on 3TC. The pt developed grade I aGvHD, then extensive cGvHD. Follow-up included blood counts, transaminase levels and HBV-DNA: these parameters showed a good control on chronic hepatitis B. Nowadays, 6 years from diagnosis and 21 months from transplant, the pt is in CR with full donor chimerism. She's still treated with 3TC without signs of acute B hepatitis recurrence or side effects. These data confirm the efficacy of 3TC in the prevention of HBV relapses in HBsAg positive pts also within a very immunosoppressive protocol as NST.
S96
Early systemic ribavirin treatment for disseminated adenovirus infection post transplant T. Carr, R. Wynn, J. Grainger, A. Will (Manchester, UK) Adenovirus is an important cause of morbidity and mortality in stem cell recipients, fatality rates of 50-80% have been reported in those patients with pneumonia or disseminated disease. We report the case of a young girl treated for disseminated adenovirus post transplant with i.v. ribavirin. Treatment was introduced following a positive PCR finding in the peripheral blood. The duration of treatment was determined by subsequent PCR results and finally withdrawn after two successive negative results. Ten days post transplant for her Hurler's disease this 1 year old child developed an upper respiratory tract infection with some tachypnoea. Adenovirus was first detected in the peripheal blood by PCR. This was followed by virus isolation from a nasopharyngeal aspirate and throat swab. Subsequently, virus was also isolated from this patient's faeces. Over the next ten days her condition continued to deteriorate and by day 21 she was having significant respiratory problems but there was no evidence of abnormal liver function and she was gaining some weight. The next ten day period saw a marked improvement in respiratory function. At day 33 her peripheral blood and nasopharyggeal aspirates were clear of virus. Following confirmatory tests at day 36 the ribavirn therapy was stopped. She continued to improve and was discharged home on day 48. This young girl has since made excellent progress, with no evidence of virus reactivation at four months. We suggest that the availability of newer, quicker diagnostic techniques such as PCR may make for earlier and more effective treatment of adenovirus infection. Quantitative PCR would further improve the management of adenovirus infection. N. Contentin, A. Francois, P. Chamouni, F. Gobet, P. Lenain, A. Stamatoullas, N. Cardinael, S. Lepretre, F. Jardin, H. Tilly (Rouen, F) Hemorrhagic cystitis (HC) is a frequent and sometime lethal complication of allogeneic bone marrow transplantation (ABMT). BK virus, a human polyomavirus is often associated with HC. Most of BKV infection in ABMT studies concern pediatric patients or symptomatic patients with HC. Cells in the urine that have viral inclusions, known as "decoy cells" (DC) are a sign of BKV replication in urinary tract. The aim of this study was to detect prospectively DC in urines from ABMT patients. Between May 2001 and October 2002, we studied urine samples of 23 consecutive ABMT patients >15 years old (5 CML, 9 AL, 3 MDS, 3 lymphoma, 2 RCC and 1 MM). Graft was collected from 18 HLA identical siblings and 5 HLA unrelated identical donors. Conditioning regimens were mostly myeloablative (4 BU-CPM and 15 CPM-TBI 12Gy) and only 4 patients received nonmyeloablative regimens. GVH prophylaxis consisted of short course MTX plus CSA (19 cases) and CSA alone for patients undergoing non-myeloablative regimens. Urinary analysis was performed weekly from day-7 to day 35 and monthly from day 35 to day 365. None of the 18 recipient available urine samples before the graft revealed presence of DC. The 16 available donor urinary samples were also normal. DC were detected after ABMT in 19 patients. Twelve patients were found to have more than two consecutive positive samples. First DC were usually seen before day 35 (10 out 12). Positivity in these cases lasted from 2 weeks to seven months. Seven patients had only sporadic DC detection appearing from day 14 to day 150. Median quantification of DC in positive samples was 4.5/mm2 (range 0.3 to 287/mm2). Among the 15 patients for whom follow-up was longer than day 100, 7 kept positive DC urines. No correlation between GVHD, immunosuppressive treatment and the presence of DC could be established. Nine patients developed HC (1 grade 1 with microscopic hematuria, 6 grade 2 with macroscopic hematuria and 2 grade 3 with hematuria and clots), 8/9 were already positive for DC when HC occurred. Conversely, 6 patients with consecutively positive samples never developed HC. In conclusion, urinary microscopic DC detection is a very easy and informative way to follow ABMT patients for risk of developing BKV infection. Presence of DC seems to precede clinical signs of HC but is not specific. This study will be complete by BKV DNA quantification.
Decoy cells detection as BK virus replication marker in allogeneic bone marrow transplantation
Risk factors and outcomes of CMV antigenemia after stem cell transplantation M. Mojtabavi Naini, A. Ghavamzadeh, M. Iravani, M. Jahani, B. Bahar, A. Mousavi, H. Gholam Natanzi, S. Gholibeikian (Tehran, IR) Objectives: Cytomegalovirus (CMV) infection remains a major problem in stem cell transplantation (SCT) recipients. Assay for CMV early antigen PP65 on circulating Leukocytes has been shown to be sensitive and specific in detecting early CMV infection. Methods: We examined the frequency, risk factors and outcomes of a positive CMV antigen assay in 335 consecutive SCT patients (male: 201, female: 134). 247 patients received related Allogeneic SCT and 88 patients received Autologous SCT. Patients with antigenemia (2 or more positive cell per 50000) were eligible to receive ganciclovir. Foscarnet was given to patients whose antigenemia did not resolve with ganciclovir therapy or in whom myelosuppression prevented ganciclovir administration. Results: 28.1% of the 335 patients developed CMV antigenemia a median of 32 days post SCT (range +1to +150). The incidence of antigenemia in autologous and related donor SCT recipients was 9% and 35% respectively(Pvalue=0.000) and was lower in seronegative patients(26% versus 46% in seropositive patient)(Pvalue=0.03).Patients with grade III-IV acute graft versus-host disease(GVHD) had 1.5 time the risk of antigenemia of patients with grade I -II acute GVHD.(Pvalue=0.023) Age at transplantation, sex, underlying disease, donor CMV serostatus, stem cell source (peripheral blood or marrow) and GVHD prophylaxis regimen did not affect the risk of CMV antigenemia. Conclusion: We conclude that significant risk factors for CMV anitgenemia include: type of transplant, recipient CMV serostatus and grade III-IV acute GVHD. D. Nachbaur, E. Gunsilius, M. Haun, C. Larcher, G. Gastl (Innsbruck, A) Background: Preliminary data suggest a faster immune recovery following non-myeloablative stem cell transplantation but the real impact on posttransplant infectious complications remains unknown. Methods: We retrospectively analysed the incidence of Cytomegalovirus (CMV) infection in twenty patients following non-myeloablative conditioning and post transplant immunosuppression with CsA/MMF. Results were compared with twenty patients receiving myeloablative transplants during the same time period and who were matched for CMV risk group and for donor origin. Results: The cumulative incidence of CMV infection/disease (CMV pp65 antigenemia) following non-myeloablative transplants was 47.3% at day 100 and 60.4% at day 200 vs 40.0% in patients receiving myeloablative transplants with not late CMV infection (beyond day 100; p value 0.1, log rank test). None of the patients died of CMV disease. The risk for CMV infection/disease in both cohorts was increased after in vivo T cell depletion with anti-thymocyte globulin (for patients with unrelated donors). Acute GVHD preceded the diagnosis of CMV infection by a median of 25 (range, 9-61) days in 73% of the patients with CMV infection following non-myeloablative transplants and by a median of 14 (range, 10-34) days in 63% of the patients with CMV infection following myeloablative transplants (differences n.s., Wilcoxon rank sum test). Multiple episodes of CMV infection were observed only in patients receiving non-myeloablative transplants. Using multivariate Cox regression analysis (including patient age, donor age, CD34+ cell number, aGVHD II°-IV°, donor CMV serostatus, recipient CMV serostatus, myeloablative vs non-myeloablative SCT, and in vivo T cell depletion) only non-myeloablative transplantation and in vivo T cell depletion were associated with a significantly increased risk for CMV infection. Conclusions: At least in our series the incidence for CMV/infection following non-myeloablative allografting seems to be increased as compared with risk-matched myeloablative transplants. When adding anti-T cell antibodies to the conditioning regimen the risk for CMV increases by up to 75%, suggesting that these patients should receive prophylactic rather than pre-emptive ganciclovir. Thorough studies of the risk of posttransplant viral infection are necessary to optimize surveillance as well as pre-emptive and prophylactic treatment strategies in the non-myeloablative transplantation setting.
Risk for cytomegalovirus infection following nonmyeloablative allogeneic stem cell transplantation
Incidence of cytomegalovirus infection after allogeneic stem cell transplantation conditioned with myeloablative and nonmyeloablative regimens I. Irrera, F. Morabito, M. Cuzzola, A. Cuzzocrea, O. Iacopino, G. Penna, G. Console, G. Messina, M. Martino, P. Iacopino (Reggio Calabria, I) Hematopoietic stem cell transplantation (HSCT) is a standardized treatment modality for malignant and nonmalignant hematologic disorders. In recent years, nonmyeloablative (N)-HSCT is increasingly being explored as therapy in patients who are not eligible for conventional myeloablative (M) HSCT. In this study we compared the incidence of cytomegalovirus (CMV) infection in 49 patients underwent HSCT from HLA-identical sibling donors treated with three different preparative approaches: M (22 cases), reduced intensity (RI, 13 cases) and N (14 cases) conditioning regimens. Seven cases were solid tumours and the remaining 42 hematological malignancies. GvHD prophylaxis consisted of cyclosporin CSA and either MTX or MMF. Thirty-one donor-recipient pairs were CMV seropositive. Surveillance from blood samples for CMV was performed by pp65 antigenemia on a weekly to biweekly basis. Fifteen cases experienced acute (3 grade 4) and 4 chronic GvHD (1 grade 4). Overall, CMV infection occurred in 15/49 (30.6%) at a median time from transplant of 40 days (range 13-93 days). All positive cases were treated with ganciclovir and the median duration of CMV infection was 6 days. Four cases died for CMV infection. The overall incidence of CMV infection was not statistically different among the 3 analysed groups of differently conditioned patients. In particular, CMV antigenemia was documented in 36.4% of M-HSCT and 35.7% of N-HSCT, while only 15.4% of the RI-HSCT showed a pp65 positivity. Finally, no difference was noted in terms of time to CMV antigenemia clearance. In conclusion, although numerically limited, our study failed to show any significant different incidence of CMV infection in patients conditioned with different regimens.
A case of progressive multifocal leukoencephalopathy (PML) following non-myeloablative HSCT for refractory CLL R. Mazza, M. Motta, D. Soligo, F. Onida, G. Lambertenghi Deliliers (Milan, I) Progressive multifocal leucoencencephalopathy (PML) is a rapidly fatal demyelinating disorder caused by JC papovavirus. A 56-yr old B-CLL HIV neg. gentleman, previously treated with several courses of CT including FMP, CTX, CHL and rituximab underwent a nonmyeloablative allo-HSCT for refractory disease. Conditioning consisted of melphalan, FMP, Alentuzumab and a single dose 200 cGy TBI. GVHD prophylaxis included CsA and MMF. The transplant was complicated by grade II mucositis and by hemolitic anemia, requiring steroid treatment. Since a CMV reactivation was documented, pre-emptive therapy with foscarnet was successfully introduced. After transplantation, a complete resolution of the lymphadenopathy was observed. On day +83 the patient presented a left homonymous hemianopsia, with no other neurological abnormalities. Brain CT documented a subcortical mixed density lesion in the right occipital area. Nine lymphocytes/ml. were detected in the CSF, where other biochemical tests, cultures, Gram and India ink stains were negative. Antibodies anti toxoplasma, aspergillus, CMV antigen p65 were also negative. MRI revealed an homogeneous signal change, myelinosis-like, in the central ponts region, and multiple cortical/subcortical dishomogeneous lesions on both hemispheres, plus cerebellar abnormalities. The picture was considered to be consistent either with CsA induced neurotoxicity or with PML. CsA was replaced by FK506. Nonetheless, visual symptoms persisted, and the patient developed ataxia and disorientation. JC viral DNA was detected by PCR in CSF, confirming the diagnosis of PML. I mmunosoppressive therapy was discontinued. However, no improvement was observed, with gradual appearence of somnolence, cognitive impairment, tremors and dismetria. On day +100, seizure occurred, and the patient eventually died on day +120. PML is commonly observed in patients with advanced HIV infection. To our knowledge, this is the first report of documented PML due to JC virus in a patient who received a nonmyeloablative HSCT for a hematological malignancy. Since nonmyeloablative transplant strategies are characterized by intense and prolonged immunosuppression, JC virus reactivation should be always suspected in the presence of neurological abnormalities occurring in patients undergoing such therapeutical procedure.
A study of donor's bone marrow stromal cells before bone marrow transplantations V. Rugal, V. Ponomarenko, V. Gontchar (St. Petersburg, RUS) Objectives: Detection of viruses on a material of blood is the key moment for diagnostics of virus infections. However the probability of virus persistence in bone marrow stromal cells speaks about necessity of virus revealing in cellular haemopoietic microenvironments. The purpose of work was studying an opportunity of virus persistence in bone marrow stromal cells as preventive action at bone marrow transplantations (BMT). Methods: Material of research were integral fragments iliac bones of 50 donor's bone marrow, 20 patients infected with a hepatitis C virus (HCV) and 20 infected with a human immunodeficiency virus (HIV). Reticular, fat and endothelial cells of a bone marrow are investigated. Methods of electronic microscopy are used. Results: The electronic microscopy has shown that all patients infected HCV and HIV in stromal cell nucleus had pathological inclusions of three types. The morphology of these inclusions testifies to maturing stages for virus-like structures which have been found out in cytoplasm of these cells. Intranuclear inclusions of one type and absence of virus-like structures in cytoplasm have been revealed at 19 of 50 donors in bone marrow stromal cells. Conclusion: The received data can testify to an opportunity of virus persistence in bone marrow stromal cells of donors. In this connection it is necessary to investigate bone marrow integral fragments to exclude an opportunity of virus influence on the recipient at BMT.
Cytomegalovirus infection: prevalence and pre-emptive therapy in autologous peripheral stem cell transplantation patients M. Bonferroni, S. Tavera, C. Castellino, M. Grasso, R. Calvi, N. Mordini, D. Mattei, M. Pistone, E. Raviolo, A. Gallamini (Cuneo, I) Cytomegalovirus (CMV) infection is a well-known complication of bone marrow transplantation either allogeneic (21-38%) or autologous (4-9%). However, predictive factors for infection in autologous peripheral stem cell transplantation (ASCT) are largely unknown. Patients and methods: between June 1997 and October 2002, 101 consecutive patients (32NHL, 52MM , 4HD, 6AML, 7CLL) underwent ASCT at our institution. Conditioning regimen consisted in MitoMel in NHL, Melphalan in MM (100-200/m2) and BEAM in AML and CLL. All patients were monitored with pp65 antigen assay twice weekly from therapy onset until dismissal. CMV prophylaxis consisted of acyclovir (400 mg p.o. twice daily) and the use of leucocyte-depleted blood products. All patients were treated with gancyclovir 5 mg/Kg or foscarnet 90 mg/kg twice daily immediately following the report of a positive test, until the resolution of the pp65 antigenemia (AG) and with an halved dose for additional 7 d. Results: we observed 8 AG: 5 were MM in RP at the transplant and 2 out of 3 NHL were heavily pretreated. Six patients were older than 60 years. The number of CD34 infused was 3.8x106/Kg. The mean time for PMN > 500 /ul and platelets > 30.000/ul was respectively 11 and 21 d. AG occurred after a mean time of 21 d.(4-45). All patients with a positive AG were febrile. CMV infection was considered the sole cause of fever in 4; 2 had antibiotic-resistant fever, 1 acute gastroenteritis and 1 pneumonia. The remaining 4 pts had concomitant sepsis: Klebsiella, Pseudomonas, Streptococcus Pneumoniae and Staphylococcus Epidermidis. 7 pts had AG levels of >5/200000 cells at presentation. The resolution of the fever and clearance of AG occurred after 5.6 d.(3-9) from the onset of antiviral treatment, but in 2 was delayed (respectively 14 and 18 d.). Of note, these two pts had the highest AG levels observed (350 and 961) and one treated with foscarnet developed acute renal failure. In conclusion: 1)the prevalence of CMV AG was 8% 2)CMV AG was detected in the first forty days post-ASCT 3)CMV AG detection was unrelated to a)haematological malignancy b)the number of CD 34+ cells infused c)duration of neutropenia 4)the relatively low frequency of AG in ASCT pts. doesn't seem to justify the routine use of pp65 survey and warrants antiviral therapy only in febrile pts.
Occurrence of CMV infection and disease in patients after non-myeloablative allogeneic hematopoietic stem cell transplantation (allo-NST) P. Zak, M. Kmonicek, L. Pliskova, L. Jebavy, M. Blaha, J. Maly, M. Skorepova (Hradec Kralove, CZ) Non myeloablative conditioning for allo-NST is an attractive strategy for reducing the toxicity of allograft procedure. In our group of pts we describe occurence of CMV infection and disease in the first six months after allo-NST. Patients: 25 pts (12 women and 13 men, median age 50 years, range 32 -69 y) underwent allo-NST from HLA identical sibling. The peripheral blood stem cells were used in all cases. Diagnoses: myeloma (n=12), B-CLL (n=2), NHL (n=6), AA (n=1), AML (n=1),Grawitz (n=3).We used two conditioning regimens: fludarabin-busulfan-ATG (Slavin,Blood 1998) (n = 9) and Flu/Cy (n = 16). Cyclosporine A was given for GVHD prophylaxis and tapered from d+100. CMV seronegative donor and recipient was in only one event, CMV seronegative recipient was in 6 events. 20 patients received high dose vala-ciclovir (4x1g/d) prophylaxis.
Methods: We determined reactivation of cytomega-lovirus using polymerase chain reaction (kit QIAGEN). CMV reactivation was defined as two consecutive CMV DNA positive results by PCR from peripheral blood.The examination of blood samples was made once a two week. On detecting CMV reacti-vation we started pre-emptive antiviral therapy (ganciclovir or foscavir). Results:CMV reactivation was detected in 10 pts. (acute GvHD II-IV grade was in 8 of 10). Replication CMV was stopped using pre-emptive ganciclovire therapy in all pts. CMV disease was observed in 3 pts with acute GvHD III or IV grade (1x CMV generalized, 1x CMV gastroente-ritis and retinitis, 1x CMV pneumonia). One pt died despite antiviral and IVIG therapy. CMV reactivation/disease was detected from 4th to 24th week (most from 8th to 10th week) after alloNST. Conclusion: In our group CMV reactivation was frequent in the 2nd and 3rd months after alloNST. Replication of CMV was detected in 10 pts (40%) despite using reduced conditioning regimen. CMV disease was observed in 3 pts (12%) with serious acute GvHD (grade III or IV).
Parvovirus B19 reactivation in a patient with acute lymphoblastic leukemia after autologous HSCT: the importance of quantitative parvovirus B19 PCR in diagnosis and treatment monitoring S. Zver, I. Preloznik Zupan, J. Pretnar (Ljubljana, SLO) Engraftment failure represents one of the most serious complications after autologous HSCT. Viruses that frequently interfere with bone marrow graft function are CMV, EBV, HHV6, HHV8 and parvovirus B19. We present a 20-year old patient with acute lymphoblastic leukemia (ALL) whose treatment was consolidated with autologous HSCT. Conditioning regimen included etoposide and fractionated TBI, followed by infusion of 1,53x106/kg CD34+ cells. Signs of bone marrow regeneration appeared on D+12 and he was discharged from the hospital on D+20. At that time he still had pancytopenia with WBC 2,4x109/L, Hb 102g/L and Plt 8x109/L and was platelet transfusions dependent. During outpatient visit on D+30 his blood counts got worse: WBC 1,3x109/L, Hb 73g/L and Plt 12x109/L. Serologic tests for already mentioned viruses and CMV PCR from peripheral blood were performed. High parvovirus B19 IgG antibody titer was found, while IgM antibodies were absent. Based on tests results on D+50 a bone marrow sample for quantitative PCR parvovirus B19 analysis was tested. Test revealed strong parvovirus B19 positivity (84,75 U/sample). We started treatment with IVIG 0.5g/kg for five consecutive days and thereafter once weekly maintenance was given. After the treatment blood counts were within normal values and PCR analysis on D+90 showed lower parvovirus B19 burden with 20,64 U/sample left. Retrospectively we performed parvovirus B19 PCR analysis of transplanted autologous bone marrow graft sample and found 5 viral copies in it.
In conclusion, temporarily insufficient autologous graft function was the c onsequence of parvovirus B19 reactivation. We suggest, that quantitative parvovirus B19 PCR analysis obtained from bone marrow should be an obligatory test in case of poor graft function after autologous or allogeneic HSCT. Based on blood counts values and dynamic of viral copies burden possible of pre-emptive IVIG therapy should be investigated The human herpes virus-6 (HHV6) diagnostic in oncohematological patients V. Gonchar, N. Roomel, E. Schilova (St. Petersburg, RUS) Objective: HHV6 is a real danger f or complications in immunocompromised patients especialy oncohematological patients (OHP). Clinical diagnostic is very difficult because there are no specifical symptoms and serological investigations showed high level of cross-match reactions with another herpes virus antigens. Methods: It was examinated by PCR blood leucocytes, urine and liquor sediments from 267 OHP with acute and chronic
